---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-24-000048"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2024-07-11T23:59:59+00:00"
generated_at: "2026-05-31T21:48:17.503630+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics appoints Sarah A. Teichmann to Board of Directors

## Summary
- Effective July 10, 2024; Class II director with term expiring at 2027 annual meeting.
- Teichmann is Chair in Stem Cell Medicine at University of Cambridge and co-chair of Human Cell Atlas.
- She receives $55,000 annual cash retainer plus initial RSU grant valued at $400,000.
- Annual RSU grant of $215,000 on annual meeting date; both grants vest over time with continued service.
- Also serves as VP at GSK and CSO at EnsoCell Therapeutics; brings genomics and leadership expertise.

## SEC filing metadata
- accession: 0001770787-24-000048
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2024-07-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000048/0001770787-24-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000048/txg-20240710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-24-000048
- JSON: https://secwatch.observer/filing/0001770787-24-000048.json
- Plain text: https://secwatch.observer/filing/0001770787-24-000048.txt

## Key facts
- Executive change
  Sarah A. Teichmann was appointed as Director at 10x Genomics, Inc..
  - Action: appointed
  - Role: Director
  source text: On July 10, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Sarah A. Teichmann to the Board of Directors as a Class II director effective immediately with a term expiring at the Company's 2027 annual meeting of stockholders or until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000048/0001770787-24-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.